Skip to main content
Journal cover image

Transcatheter Aortic Valve Replacement of Failed Surgically Implanted Bioprostheses: The STS/ACC Registry.

Publication ,  Journal Article
Tuzcu, EM; Kapadia, SR; Vemulapalli, S; Carroll, JD; Holmes, DR; Mack, MJ; Thourani, VH; Grover, FL; Brennan, JM; Suri, RM; Dai, D; Svensson, LG
Published in: J Am Coll Cardiol
July 24, 2018

BACKGROUND: Valve-in-valve (ViV) transcatheter aortic valve replacement (TAVR) has been shown to be feasible, yet the safety and efficacy in relation to native valve (NV) TAVR are not known. OBJECTIVES: This study sought to evaluate the safety and effectiveness of ViV TAVR for failed surgical aortic valve replacement (SAVR) by comparing it with the benchmark of NV TAVR. METHODS: Patients who underwent ViV-TAVR (n = 1,150) were matched 1:2 (on sex, high or extreme risk, hostile chest or porcelain aorta, 5-m-walk time, and Society of Thoracic Surgeons Predicted Risk of Mortality for reoperation) to patients undergoing NV-TAVR (n = 2,259). Baseline characteristics, procedural data, and in-hospital outcomes were obtained from the Transcatheter Valve Therapy Registry. The 30-day and 1-year outcomes were obtained from linked Medicare administrative claims data. RESULTS: Unadjusted analysis revealed lower 30-day mortality (2.9% vs. 4.8%; p < 0.001), stroke (1.7% vs. 3.0%; p = 0.003), and heart failure hospitalizations (2.4% vs. 4.6%; p < 0.001) in the ViV-TAVR compared with NV-TAVR group. Adjusted analysis revealed lower 30-day mortality (hazard ratio: 0.503; 95% confidence interval: 0.302 to 0.839; p = 0.008), lower 1-year mortality (hazard ratio: 0.653; 95% confidence interval: 0.505 to 0.844; p = 0.001), and hospitalization for heart failure (hazard ratio: 0.685; 95% confidence interval: 0.500 to 0.939; p = 0.019) in the ViV-TAVR group. Patients in the ViV-TAVR group had higher post-TAVR mean gradient (16 vs. 9 mm Hg; p < 0.001), but less moderate or severe aortic regurgitation (3.5% vs. 6.6%; p < 0.001). Post-TAVR gradients were highest in small SAVRs and stenotic SAVRs. CONCLUSIONS: Comparison with the benchmark NV-TAVR shows ViV-TAVR to be a safe and effective procedure in patients with failed SAVR who are at high risk for repeat surgery.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Am Coll Cardiol

DOI

EISSN

1558-3597

Publication Date

July 24, 2018

Volume

72

Issue

4

Start / End Page

370 / 382

Location

United States

Related Subject Headings

  • United States
  • Treatment Outcome
  • Transcatheter Aortic Valve Replacement
  • Risk Assessment
  • Reoperation
  • Registries
  • Prosthesis Failure
  • Outcome and Process Assessment, Health Care
  • Mortality
  • Male
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Tuzcu, E. M., Kapadia, S. R., Vemulapalli, S., Carroll, J. D., Holmes, D. R., Mack, M. J., … Svensson, L. G. (2018). Transcatheter Aortic Valve Replacement of Failed Surgically Implanted Bioprostheses: The STS/ACC Registry. J Am Coll Cardiol, 72(4), 370–382. https://doi.org/10.1016/j.jacc.2018.04.074
Tuzcu, E Murat, Samir R. Kapadia, Sreekanth Vemulapalli, John D. Carroll, David R. Holmes, Michael J. Mack, Vinod H. Thourani, et al. “Transcatheter Aortic Valve Replacement of Failed Surgically Implanted Bioprostheses: The STS/ACC Registry.J Am Coll Cardiol 72, no. 4 (July 24, 2018): 370–82. https://doi.org/10.1016/j.jacc.2018.04.074.
Tuzcu EM, Kapadia SR, Vemulapalli S, Carroll JD, Holmes DR, Mack MJ, et al. Transcatheter Aortic Valve Replacement of Failed Surgically Implanted Bioprostheses: The STS/ACC Registry. J Am Coll Cardiol. 2018 Jul 24;72(4):370–82.
Tuzcu, E. Murat, et al. “Transcatheter Aortic Valve Replacement of Failed Surgically Implanted Bioprostheses: The STS/ACC Registry.J Am Coll Cardiol, vol. 72, no. 4, July 2018, pp. 370–82. Pubmed, doi:10.1016/j.jacc.2018.04.074.
Tuzcu EM, Kapadia SR, Vemulapalli S, Carroll JD, Holmes DR, Mack MJ, Thourani VH, Grover FL, Brennan JM, Suri RM, Dai D, Svensson LG. Transcatheter Aortic Valve Replacement of Failed Surgically Implanted Bioprostheses: The STS/ACC Registry. J Am Coll Cardiol. 2018 Jul 24;72(4):370–382.
Journal cover image

Published In

J Am Coll Cardiol

DOI

EISSN

1558-3597

Publication Date

July 24, 2018

Volume

72

Issue

4

Start / End Page

370 / 382

Location

United States

Related Subject Headings

  • United States
  • Treatment Outcome
  • Transcatheter Aortic Valve Replacement
  • Risk Assessment
  • Reoperation
  • Registries
  • Prosthesis Failure
  • Outcome and Process Assessment, Health Care
  • Mortality
  • Male